<DOC>
	<DOC>NCT02277704</DOC>
	<brief_summary>This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL â€”a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible subjects will return regularly to the study clinic for weekly or biweekly visits for assessments of efficacy and safety.</brief_summary>
	<brief_title>Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions</brief_title>
	<detailed_description />
	<criteria>Male or female between 18 and 65 years of age Diagnosed with current PTSD as defined by the ClinicianAdministered PTSD Scale for DSM5 (CAPS5), For patients with a qualifying Index trauma(s) resulting in PTSD that occurred during military service, military contractor, Department of Homeland Security or law enforcement Willing and able to withdraw and refrain from specific therapies (ask PI) Use medically acceptable form of contraception (female only) Signed informed consent Significant traumatic brain injury Severe depression Bipolar and psychotic disorders Increase risk of suicide Significant clinical (cardiac, systemic infection, drug/alcohol abuse) or laboratory abnormalities (including positivity for Hep B, Hep C, HIV) Unable to washout specific medications (ask PI) History of violent behavior within past 2 years, unrelated to work duties History of drug or alcohol abuse within past 6 months Positive illegal substance test Known hypersensitivity to cyclobenzaprine Others: seizure disorders, uncontrolled sleep apnea, BMI&gt;40 Participation in an investigational study in past 30 days In the process of litigating for compensation for a psychiatric disorder Females that are pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Military-related PTSD and other related conditions</keyword>
</DOC>